|
EMCDDA–Europol Joint Report on a new psychoactive substance: N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]-furan-2-carboxamide (furanylfentanyl) |
new psychoactive substances (NPS) | synthetic drugs |
|
High-risk drug use and new psychoactive substances |
death | new psychoactive substances (NPS) | problem drug use | recreational drugs | synthetic stimulants |
|
Report on the risk assessment of methyl 2-[[1-(cyclohexylmethyl)-1H-indole-3-carbonyl]amino]-3,3-dimethylbutanoate (MDMB-CHMICA) in the framework of the Council Decision on new psychoactive substances |
new psychoactive substances (NPS) |
|
EMCDDA–Europol Joint Report on a new psychoactive substance: N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide (acryloylfentanyl) |
new psychoactive substances (NPS) |
|
New psychoactive substances in Europe: legislation and prosecution — current challenges and solutions |
law | new psychoactive substances (NPS) | policy |
|
Report on the risk assessment of 1-phenyl-2-(pyrrolidin-1-yl)pentan-1-one (α-pyrrolidinovalerophenone, α-PVP) |
new psychoactive substances (NPS) | scientific committee |
|
Health responses to new psychoactive substances (Perspectives on Drugs) |
best practice | emerging topics | harm reduction | health effects | new psychoactive substances (NPS) | treatment |
|
EMCDDA–Europol 2015 Annual Report on the implementation of Council Decision 2005/387/JHA |
activities | markets | new psychoactive substances (NPS) | policy | seizures | trafficking |
|
EMCDDA–Europol Joint Report on MDMB-CHMICA |
crime | new psychoactive substances (NPS) |
|
Health responses to new psychoactive substances |
best practice | emerging topics | health effects | injection | new psychoactive substances (NPS) | prevention | prison | problem drug use | recreational drugs | synthetic drugs | synthetic stimulants | treatment | young people |